Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Oxodipine 是一种二氢吡啶型钙拮抗剂 ,抑制了KCl 诱导的兔主动脉收缩,降低了效力较低的大鼠心室试纸收缩的心脏力量。在大鼠培养的新生儿心室肌细胞中,Oxodipine 降低了L 型Ca 电流(I),IC 为0.24μM,对T 型Ca 电流(I)的IC 为0.41μM。Oxodipine 会使小鼠便秘和狗牙龈增生。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 530 | 现货 | ||
5 mg | ¥ 1,230 | 现货 | ||
10 mg | ¥ 1,830 | 现货 | ||
25 mg | ¥ 3,530 | 现货 | ||
50 mg | ¥ 4,800 | 现货 | ||
100 mg | ¥ 6,830 | 现货 | ||
500 mg | ¥ 13,700 | 现货 |
产品描述 | Oxodipine, a dihydropyridine-type calcium antagonist , inhibited KCl-induced aortic contraction in rabbits and reduced cardiac force in less potent rat ventricular test-paper contractions. In rat cultured neonatal ventricular myocytes, Oxodipine reduced L-type Ca currents (I) with an IC of 0.24 μM, and against T-type Ca currents (I) with an IC of 0.41 μM. Oxodipine causes constipation in mice and gingival hyperplasia in dogs. |
靶点活性 | I(CaL):0.24 µM |
体外活性 | In aortic rings, Oxodipine (10(-11)-10(-6) M) inhibited in a concentration-dependent manner the contractions induced by high K+ (IC50 = 9.0 +/- 4.0 x 10(-10) M) or by Ca2+ in high K+ solution (IC50 = 6.2 +/- 2.4 x 10(-9) M). In mesenteric resistance vessels, Oxodipine inhibited the contractions induced by high K+(IC50 = 5.2 +/- 3.1 x 10(-10)).[4] |
体内活性 | Oxodipine (5, 20, and 50 μg/kg; anesthetized dogs), a new dihydropyridine calcium channel blocker, ineffective at 5 μg/kg, whereas doses of 20 and 50 μg/kg of oxodipine elicited a decrease in blood pressure with no change in heart rate. These results suggest that, in contrast to other first-generation dihydropyridines, oxodipine exerts a relatively specific action on blood vessels without significant intrinsic negative chronotropic properties in anesthetized sinoaortic-denervated dogs.[4] |
分子量 | 359.37 |
分子式 | C19H21NO6 |
CAS No. | 90729-41-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Oxodipine 90729-41-2 Membrane transporter/Ion channel Metabolism Calcium Channel Inhibitor inhibitor inhibit